MAGEC3 and ovarian carcinoma: Previously, we described a linkage between early-onset ovarian cancers [42] and MAGEC3 [43,44] and more recently found that MAGEC3 is a potential prognostic biomarker in ovarian cancer, as loss levels were associated with a favorable progression-free survival (PFS) in ovarian cancer patients [36].